Author:
Magagnoli Joseph,Yerramothu Praveen,Ambati Kameshwari,Cummings Tammy,Nguyen Joseph,Thomas Claire C.,Wang Shao-bin,Cheng Kaitlyn,Juraev Maksud,Dholkawala Roshni,Nagasaka Ayami,Ambati Meenakshi,Nagasaka Yosuke,Ban Ashley,Ambati Vidya L.,Sutton S. Scott,Gelfand Bradley D.,Ambati Jayakrishna
Abstract
AbstractInnate immune signaling through the NLRP3 inflammasome has been implicated in the pathogenesis of Alzheimer’s disease (AD), the most prevalent form of dementia. We previously demonstrated that nucleoside reverse transcriptase inhibitors (NRTIs), drugs approved to treat HIV and hepatitis B infections, also inhibit inflammasome activation. Here we report that in humans, NRTI exposure was associated with a significantly lower incidence of AD in two of the largest health insurance databases in the United States. Treatment of aged 5xFAD mice (a mouse model of amyloid-β deposition that expresses five mutations found in familial AD) with Kamuvudine-9 (K-9), an NRTI-derivative with enhanced safety profile, reduced Aβ deposition and reversed their cognitive deficit by improving their spatial memory and learning performance to that of young wild-type mice. These findings support the concept that inflammasome inhibition could benefit AD and provide a rationale for prospective clinical testing of NRTIs or K-9 in AD.
Publisher
Cold Spring Harbor Laboratory
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献